Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 5/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235387 | 0.80 | LMNA (0.40) | LMNAPDE3BPDE3ASYKLRRK2 | |
| SCHEMBL10187834 | 0.80 | LMNA (0.40) | LMNAPDE3BPDE3AKRASSOS1 | |
| SCHEMBL14213424 | 0.77 | LMNA (0.37) | LMNAPDE3BPDE3ASYKKRAS | |
| SCHEMBL18850851 | 0.71 | MARK3 (0.36) | S100A4CYP2C19 | |
| SCHEMBL15743906 | 0.70 | LMNA (0.42) | LMNAPDE3BPDE3AELANEPRTN3 | |
| SCHEMBL89095 | 0.69 | PDE3B (0.52) | LMNAPDE3BPDE3AELANEPRTN3 | |
| SCHEMBL17813516 | 0.69 | HTR1D (0.41) | PDE3BPDE3A | |
| SCHEMBL10239074 | 0.67 | SYK (0.41) | LMNAPDE3BPDE3ASYKCCR1 | |
| SCHEMBL16362032 | 0.66 | NISCH (0.52) | LMNAPDE3BPDE3AELANEPRTN3 | |
| SCHEMBL13960942 | 0.66 | LMNA (0.41) | LMNAPDE3BPDE3AKRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040543-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8193197-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | LMNA 4265/4885PDE3B 1092/4885PDE3A 1437/4885 |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | JAK1, JAK3, JAK2 | LMNA 4864/4885PDE3B 555/4885PDE3A 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.